199 related articles for article (PubMed ID: 21140161)
1. The efficacy of intravitreal bevacizumab for idiopathic central serous chorioretinopathy.
Lim JW; Kim MU
Graefes Arch Clin Exp Ophthalmol; 2011 Jul; 249(7):969-74. PubMed ID: 21140161
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab injection for central serous chorioretinopathy.
Lim SJ; Roh MI; Kwon OW
Retina; 2010 Jan; 30(1):100-6. PubMed ID: 20010322
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab injection for central serous chorioretinopathy.
Nowroozzadeh MH
Retina; 2010 Sep; 30(8):1322-3; author reply 1323. PubMed ID: 20827148
[No Abstract] [Full Text] [Related]
4. Intravitreal bevacizumab injection for central serous chorioretinopathy.
Chhablani JK; Narayanan R
Retina; 2010 Sep; 30(8):1323-24; author reply 1324. PubMed ID: 20661171
[No Abstract] [Full Text] [Related]
5. Results of one-year follow-up examinations after intravitreal bevacizumab administration for chronic central serous chorioretinopathy.
Inoue M; Kadonosono K; Watanabe Y; Kobayashi S; Yamane S; Arakawa A
Ophthalmologica; 2011; 225(1):37-40. PubMed ID: 20693820
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study.
Artunay O; Yuzbasioglu E; Rasier R; Sengul A; Bahcecioglu H
Curr Eye Res; 2010 Feb; 35(2):91-8. PubMed ID: 20136418
[TBL] [Abstract][Full Text] [Related]
7. FLAT IRREGULAR PIGMENT EPITHELIUM DETACHMENT IN CENTRAL SEROUS CHORIORETINOPATHY: A Form of Pachychoroid Neovasculopathy?
Hwang H; Kim JY; Kim KT; Chae JB; Kim DY
Retina; 2020 Sep; 40(9):1724-1733. PubMed ID: 31584559
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy.
Schaal KB; Hoeh AE; Scheuerle A; Schuett F; Dithmar S
Eur J Ophthalmol; 2009; 19(4):613-7. PubMed ID: 19551677
[TBL] [Abstract][Full Text] [Related]
9. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial.
Bae SH; Heo J; Kim C; Kim TW; Shin JY; Lee JY; Song SJ; Park TK; Moon SW; Chung H
Ophthalmology; 2014 Feb; 121(2):558-65. PubMed ID: 24268858
[TBL] [Abstract][Full Text] [Related]
10. Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy.
Nicolò M; Zoli D; Musolino M; Traverso CE
Am J Ophthalmol; 2012 Mar; 153(3):474-480.e1. PubMed ID: 22019224
[TBL] [Abstract][Full Text] [Related]
11. Choroidal thickness and choroidal blood flow after intravitreal bevacizumab injection in eyes with central serous chorioretinopathy.
Okamoto M; Matsuura T; Ogata N
Ophthalmic Surg Lasers Imaging Retina; 2015 Jan; 46(1):25-32. PubMed ID: 25559505
[TBL] [Abstract][Full Text] [Related]
12. Aqueous humor and plasma levels of vascular endothelial growth factor and interleukin-8 in patients with central serous chorioretinopathy.
Lim JW; Kim MU; Shin MC
Retina; 2010 Oct; 30(9):1465-71. PubMed ID: 20526231
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics of responders to intravitreal bevacizumab in central serous chorioretinopathy patients.
Kim GA; Rim TH; Lee SC; Byeon SH; Koh HJ; Kim SS; Lee CS
Eye (Lond); 2015 Jun; 29(6):732-40; quiz 741. PubMed ID: 25952951
[TBL] [Abstract][Full Text] [Related]
14. TWELVE-MONTH EFFICACY OF INTRAVITREAL BEVACIZUMAB INJECTION FOR CHRONIC, ATYPICAL, OR RECURRENT CENTRAL SEROUS CHORIORETINOPATHY.
Chung YR; Kim JW; Song JH; Park A; Kim MH
Retina; 2019 Jan; 39(1):134-142. PubMed ID: 29077604
[TBL] [Abstract][Full Text] [Related]
15. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy.
Bae SH; Heo JW; Kim C; Kim TW; Lee JY; Song SJ; Park TK; Moon SW; Chung H
Am J Ophthalmol; 2011 Nov; 152(5):784-92.e2. PubMed ID: 21742303
[TBL] [Abstract][Full Text] [Related]
16. SUBFOVEAL CHOROIDAL THICKNESS CHANGES IN TREATED IDIOPATHIC CENTRAL SEROUS CHORIORETINOPATHY AND THEIR ASSOCIATION WITH RECURRENCE.
Kim DY; Joe SG; Yang HS; Lee JY; Kim JG; Yoon YH
Retina; 2015 Sep; 35(9):1867-74. PubMed ID: 25946693
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal injection of triamcinolone combined with bevacizumab for choroidal neovascularization associated with large retinal pigment epithelial detachment in age-related macular degeneration.
el Matri L; Chebil A; Kort F; Bouraoui R; Baklouti K; Mghaieth F
Graefes Arch Clin Exp Ophthalmol; 2010 Jun; 248(6):779-84. PubMed ID: 20169357
[TBL] [Abstract][Full Text] [Related]
18. Association between the efficacy of photodynamic therapy and indocyanine green angiography findings for central serous chorioretinopathy.
Inoue R; Sawa M; Tsujikawa M; Gomi F
Am J Ophthalmol; 2010 Mar; 149(3):441-6.e1-2. PubMed ID: 20172070
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial.
Zhang H; Liu ZL; Sun P; Gu F
Am J Ophthalmol; 2012 Feb; 153(2):300-306.e1. PubMed ID: 21982109
[TBL] [Abstract][Full Text] [Related]
20. Regression of serous macular detachment due to peripheral exudative hemorrhagic chorioretinopathy following intravitreal bevacizumab.
Barkmeier AJ; Kadikoy H; Holz ER; Carvounis PE
Eur J Ophthalmol; 2011; 21(4):506-8. PubMed ID: 21240857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
